Scott Davis, DPM
Foot Surgery · Bakersfield, CANPI 1821189812
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Smith+Nephew at 48.6% of the total. That places this record below the midpoint for foot surgery clinicians in CA, where the typical reported total is $733.
Across 22 payments — averaging $29.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$316
- Stryker$151
- Bioventus LLC$122
- Cornerstone Medical Associates, Inc.$47
- Melinta Therapeutics, LLC$15
What the payments were for
- Food & beverage$651100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 16 | $316 |
| Stryker | 1 | $151 |
| Bioventus LLC | 2 | $122 |
| Cornerstone Medical Associates, Inc. | 2 | $47 |
| Melinta Therapeutics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$651 in reported general payments places this provider in the 45th percentile of 71 foot surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 54 | $897 |
| Terbinafine Hcl | 40 | $700 |
| Ciclopirox | 24 | $627 |
| Methylprednisolone | 110 | $573 |
| Cephalexin | 19 | $534 |
| Cefazolin Sodium | 11 | $363 |
| Diclofenac Sodium | 18 | $301 |
| Triamcinolone Acetonide | 18 | $117 |
| Pregabalin | 18 | $100 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 12 | $80 |
| Meloxicam | 17 | $54 |
Paid to pharmacies, not to this prescriber.
Other foot surgery in Bakersfield
- Timothy SillBakersfield$224
- Lee MarekBakersfield$196
- Alexander ReyzelmanSan Francisco$137K
- Helen ShnolBeverly Hills$22K
- Benedict ChingFountain Valley$19K
- Zachary KramerEncinitas$14K
- Tara HarringtonElk Grove$12K
- Jack MorganMonterey Park$11K
- Jaehyun KimSunnyvale$7K
- Ingrid EdelmanSan Diego$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.